17 results about "Lipid emulsion" patented technology

The present invention relates to glucose solutions for parenteral administration comprising glucose and a pharmaceutically acceptable form of iron, as well as to containers comprising, in separate chambers, said glucose solutions and a lipid emulsion for parenteral administration and / or an amino acid solution for parenteral administration.

The present invention provides a purified egg yolk lecithin and a preparation method thereof comprising extraction, by using specific solvents and conditions, the PC / PE ratio is increased, and the influence on the environment is reduced. The invention also provides lipid emulsions and parenteral nutritional products comprising the purified egg yolk lecithin obtained by the methods of the invention.

Abstract: A piperazine-substituted phenol derivative having the structure represented by formula (I) is provided. This compound not only has good salt-forming properties and excellent water solubility to meet pharmaceutical requirements, but also has a low minimum effective dose of anesthetics, rapid onset of action, and rapid recovery. This overcomes the drawbacks of prodrugs and lipid emulsion formulations of propofol and ciprofol, and is expected to be used in the preparation of drugs with sedative, hypnotic, and / or anesthetic effects and drugs for controlling status epilepticus. TIFF2025535407000076.tif41170

The present invention relates to a pharmaceutical composition that comprises a lipid emulsion and thus inhibits nitric oxide production, thereby inhibiting vasodilation.

The present invention relates to a lipid emulsion for total parenteral and enteral (oral or through gastric or duodenal tube) nutrition. The lipid emulsions have advantageous immunomodulatory, anti-inflammatory and anti-diabetic effects. The lipid emulsion may also comprise a drug, may be used as an antidote, or for reversing negative effects from ischemia-reperfusion injury.

The present invention relates to lipid emulsions for parenteral administration comprising an oil phase and a pharmaceutically acceptable form of selenium, as well as to containers comprising, in separate chambers, said emulsions and an amino acid solution for parenteral administration and / or a glucose solution for parenteral administration.

The present invention relates to amino acid solutions for parenteral administration comprising amino acids and a pharmaceutically acceptable form of copper, as well as to containers comprising, in separate chambers, said amino acid solutions and a lipid emulsion for parenteral administration and / or a glucose solution for parenteral administration.

The invention provides a lipid emulsion with improved stability and oxidation resistance as well as a preparation method and application of the lipid emulsion. The lipid emulsion comprises a wall material, lipid and an emulsifier, wherein the wall material is prepared from raw materials including polysaccharide and protein through freeze-drying treatment and dry heat treatment in sequence; the emulsifier is selected from at least one of soybean lecithin, sodium caseinate and mono-and diglycerol fatty acid esters; the lipid comprises at least one of algae oil, krill oil, fish oil and palm oil; the treatment temperature of the dry heat treatment is 60-80 DEG C, and the treatment time is 8-20 hours. The lipid emulsion provided by the invention has the characteristics of high stability and capability of inhibiting nutritional ingredients from being oxidized.

A piperazine substituted phenol derivative and its applications in pharmaceutical chemistry are provided. The compound, depicted by formula I, exhibits excellent salt formation properties and water solubility, meeting formulation requirements. It also has a low minimum effective anesthetic dose, enabling rapid onset and recovery. This addresses the drawbacks of propofol and ciprofol prodrugs and lipid emulsions. The compound shows promise in developing drugs with sedative, hypnotic, and / or anesthetic effects, as well as in drugs for controlling status epilepticus.

The present invention relates to a specific lipid emulsion comprising ≥ 5 % stearidonic acid and ≥ 15 % α-linolenic acid for use in neuroprotection, neuroregeneration and neurodevelopment.

A particle includes at least one or more kinds of substrate and lipid nanoparticles. The lipid nanoparticles are dispersed in the substrate and contain a physiologically active substance. The lipid nanoparticles are one or more kinds selected from liposomes, lipid emulsions, and solid lipid nanoparticles. A corresponding powder inhalant contains the particle. A production method for the particle includes granulating and drying, in which a suspension containing the substrate and the lipid nanoparticles are granulated and dried in a gas medium.

The invention provides a purified egg yolk lecithin and a preparation method comprising DMC purification, and environment-friendly solvents and conditions are used, so that the influence on the environment is reduced. The invention also provides a lipid emulsion comprising the purified egg yolk lecithin obtained by the method of the invention.

The present disclosure relates to lipid emulsions for parenteral administration, comprising 10 to 30% of a lipid phase comprising soybean oil, medium-chain triglycerides (MCT), olive oil and fish oil and less than 25 mg, preferably less than 20 mg, campesterol, less than 30 mg, preferably less than 25 mg, stigmasterol and less than 120 mg, preferably less than 100 mg, betasitosterol per 100 g of the lipid phase. The present disclosure also relates to the lipid emulsions according to the present disclosure for providing parenteral nutrition, in particular to neonates, as well as to methods for manufacturing the lipid emulsions according to the present disclosure.

A lipid or enzyme-modified lipid emulsion with excellent stability at low temperatures is developed. The lipid or enzyme-modified lipid emulsion includes an aqueous phase comprising 1.0-15 wt % modified starch or a polyglycerol ester of fatty acids (PGE) and 30-50 wt % organic solvent; and an oil phase comprising 1.0-20 wt % lipid or enzyme-modified lipid, such as enzyme-modified butter flavor or enzyme-modified plant oil, and 5.0-25 wt % edible oil. The lipid or enzyme-modified lipid emulsion may further include 0.1-5.0 wt % crystallization inhibitor and / or 0-15 wt % weighting agent. The enzyme-modified butter flavor or enzyme-modified plant oil in the lipid or enzyme-modified lipid emulsion is selected from the group consisting of monoglyceride, diglyceride, triglyceride, and a mixture thereof. A method for preparing the lipid or enzyme-modified lipid emulsion is also developed.

The present disclosure relates to improved lipid emulsions for providing parenteral nutrition, including ready-to-use parenteral nutrition formulations comprising such lipid emulsions. More particularly, the present disclosure is directed to improved lipid formulations or emulsions including multi-chamber containers comprising same, wherein the lipid emulsion contains DHA, EPA, and ARA in an optimized concentration and ratio, optionally in combination with choline and defined levels of phytosterols. The present disclosure further relates to methods of avoiding and / or treating liver damage and / or inflammation, and to methods for improving fatty acid profiles in plasma and certain tissues or organs especially of pediatric patients.

The present disclosure provides lipid emulsions comprising at least 20 percent (w / v) lipid with an average particle size of about 200 to about 300 nm, and use thereof to treat subjects in need of lipid emulsion therapy.

The invention relates to a low-irritation soothing composition and application thereof, and belongs to the technical field of skin care products. The low-irritation soothing composition is prepared from the following components in percentage by mass: 0.05 to 0.2 weight percent of kava pacifier, 0.3 to 1.0 weight percent of pink red plum extract and 1.8 to 2.5 weight percent of mixed emulsifier which is prepared from cetostearyl alcohol and glyceryl stearate, and the mass ratio of the cetostearyl alcohol to the glyceryl stearate is (2.5 to 3.5) to 1; the composition comprises the following components in percentage by weight: 2.0-5.0% of a humectant, 0.4-1.0% of a preservative, 0-2.0% of cosmetically acceptable auxiliary materials and the balance of water. Through the synergistic effect of the low-concentration kava pacifier and the pink red plum extract and by adopting a low-total-fat emulsification system, a fine and stable O / W emulsion is formed, the percutaneous moisture loss is reduced, and a physical barrier is repaired; the microenvironment with low inflammation, low oxidation and flora balance is maintained together, and ideal conditions are provided for barrier repair.